Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.041 AUD | +2.50% | -8.89% | -44.59% |
Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Feb. 29 | Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.95M 18.04M |
---|---|---|---|---|---|
Net income 2024 * | -29M -43.77M | Net income 2025 * | -31M -46.79M | EV / Sales 2024 * | - |
Net Debt 2024 * | 5.28M 7.96M | Net Debt 2025 * | 3.96M 5.97M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.38
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.94% |
1 day | +2.50% | ||
1 week | -8.89% | ||
Current month | -6.82% | ||
1 month | -18.00% | ||
3 months | -39.71% | ||
6 months | -46.05% | ||
Current year | -44.59% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 21-09-12 | |
Antje Wegener
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gitasha Chand
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Hopper
CHM | Chairman | 68 | 21-02-10 |
Leila Alland
BRD | Director/Board Member | 61 | 22-06-05 |
Chief Executive Officer | - | 21-09-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 0.041 | +2.50% | 367 724 |
24-05-03 | 0.04 | +11.11% | 1,063,876 |
24-05-02 | 0.036 | -10.00% | 767,473 |
24-05-01 | 0.04 | -9.09% | 513,923 |
24-04-30 | 0.044 | -2.22% | 693,896 |
Delayed Quote Australian S.E., May 06, 2024 at 02:10 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.59% | 11.95M | |
+26.08% | 662B | |
+21.72% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.51% | 198B | |
-10.59% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- RAD Stock